Related Experiment Video

Updated: Jun 24, 2026

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
12:33

A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination

Published on: June 25, 2014

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

Bo Ahrén1

  • 1Department of Clinical Sciences, Division of Medicine, Lund University, SE-221 84 Lund, Sweden. Bo.Ahren@med.lu.se

Nature Reviews. Drug Discovery
|April 15, 2009
PubMed

Insights

Islet dysfunction drives type 2 diabetes. Targeting G protein-coupled receptors (GPCRs) in beta-cells, like the GLP1 receptor, offers a promising therapeutic strategy for improving insulin secretion and beta-cell mass.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Islet dysfunction, marked by impaired insulin secretion, elevated glucagon, and reduced beta-cell mass, is key in type 2 diabetes pathophysiology.
  • G protein-coupled receptors (GPCRs) on islet beta-cells regulate islet function and represent viable therapeutic targets.
  • The success of GLP1 receptor agonists and DPP4 inhibitors highlights the therapeutic potential of targeting beta-cell GPCRs.

Purpose of the Study:

  • To review the expression, signaling, and function of GPCRs in islet beta-cells.
  • To highlight the therapeutic potential of targeting islet beta-cell GPCRs for type 2 diabetes treatment.

Main Methods:

  • Literature review of GPCRs in islet beta-cells.
  • Analysis of GPCR expression, signaling pathways, and functional roles.
  • Evaluation of therapeutic strategies targeting GPCRs for type 2 diabetes.

Main Results:

  • Several GPCRs, including GLP1 and GIP receptors, are expressed in islet beta-cells and modulate insulin and glucagon secretion.
  • Targeting the GLP1 receptor has shown efficacy in stimulating insulin secretion, inhibiting glucagon secretion, and potentially increasing beta-cell mass.
  • Other GPCRs (lipid, peptide, biogenic amine) also play roles in islet function.

Conclusions:

  • Islet beta-cell GPCRs are critical regulators of glucose homeostasis and are promising targets for type 2 diabetes therapies.
  • Modulating specific GPCRs offers a multifaceted approach to managing type 2 diabetes by addressing insulin secretion, glucagon levels, and beta-cell mass.

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...